Literature DB >> 9308710

Adverse effects of sulindac used for prevention of colorectal cancer.

H Ishikawa, I Akedo, T Suzuki, H Narahara, T Otani.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9308710     DOI： 10.1093/jnci/89.18.1381

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  6 in total

Review 1.  Chemoprevention in familial adenomatous polyposis.

Authors:  Brian Kim; Francis M Giardiello
Journal:  Best Pract Res Clin Gastroenterol       Date:  2011-08       Impact factor: 3.043

2.  Long-term chemoprevention in patients with adenomatous polyposis coli: an observational study.

Authors:  Teresa M Neuhann; Katharina Haub; Verena Steinke-Lange; Monika Morak; Andreas Laner; Melanie Locher; Elke Holinski-Feder
Journal:  Fam Cancer       Date:  2022-05-16       Impact factor: 2.375

3.  Chemoprevention of colorectal cancer in Japan: a brief introduction to current clinical trials.

Authors:  Hideki Ishikawa; Tomiyo Nakamura; Atsuko Kawano; Nobuhisa Gondo; Toshiyuki Sakai
Journal:  J Gastroenterol       Date:  2009-01-16       Impact factor: 7.527

4.  Sodium salicylate and 5-aminosalicylic acid synergistically inhibit the growth of human colon cancer cells and mouse intestinal polyp-derived cells.

Authors:  Hideki Takakura; Mano Horinaka; Ayaka Imai; Yuichi Aono; Toshimasa Nakao; Shingo Miyamoto; Yosuke Iizumi; Motoki Watanabe; Takumi Narita; Hideki Ishikawa; Michihiro Mutoh; Toshiyuki Sakai
Journal:  J Clin Biochem Nutr       Date:  2021-12-18       Impact factor: 3.114

5.  Preventive effects of low-dose aspirin on colorectal adenoma growth in patients with familial adenomatous polyposis: double-blind, randomized clinical trial.

Authors:  Hideki Ishikawa; Keiji Wakabayashi; Sadao Suzuki; Michihiro Mutoh; Keiji Hirata; Tomiyo Nakamura; Ikuko Takeyama; Atsuko Kawano; Nobuhisa Gondo; Takashi Abe; Shinkan Tokudome; Chiho Goto; Nariaki Matsuura; Toshiyuki Sakai
Journal:  Cancer Med       Date:  2013-02-03       Impact factor: 4.452

Review 6.  Inhibitory-κB Kinase (IKK) α and Nuclear Factor-κB (NFκB)-Inducing Kinase (NIK) as Anti-Cancer Drug Targets.

Authors:  Andrew Paul; Joanne Edwards; Christopher Pepper; Simon Mackay
Journal:  Cells       Date:  2018-10-20       Impact factor: 6.600
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.